In his closing thoughts, Dr De Castro provides a final overview of the ASH conference, highlighting updates in PNH treatment. Carlos M. De Castro, MD: I’d love to say we need more studies, studying ...

“It’s widely accepted and appreciated that paroxysmal nocturnal hemoglobinuria [PNH] is a rare disease, with most countries worldwide having only 1 or 2 experts who are interested in the disease and ...

Ilene Weitz, MD, details a few abstracts on paroxysmal nocturnal hemoglobinuria (PNH) treatments that will be presented at ASH 2024, particularly data on danicopan as an add-on to ravulizumab or ...

These findings suggest that clone size at PNH onset may serve as a prognostic factor for disease burden and MAVEs/TEs, aiding in clinical decision-making about treatment initiation or maintenance. In ...

AJMC ®: Paroxysmal nocturnal hemoglobinuria (PNH) is 1 of several complement-driven diseases. Can you describe its clinical presentation? DE CASTRO: PNH presents heterogeneously. One of the 3 ...

Healio spoke with Marcel P. Devetten, MD, associate professor of oncology and hematology at University of Nebraska Medical Center, about multidisciplinary care in paroxysmal nocturnal hemoglobinuria ...

Please provide your email address to receive an email when new articles are posted on . Crovalimab provided disease control and proved noninferior to a current standard-of-care treatment for certain ...

A 23-year-old Florida woman has been temporarily blinded and bruised after allegedly being required to receive multiple vaccines before a blood transfusion for a rare autoimmune disorder. Alexis ...

Paroxysmal nocturnal hemoglobinuria leaves red blood cells more vulnerable to destruction. A common side effect is blood clots, known as thrombosis. This is largely preventable with medication to ...

Because paroxysmal nocturnal hemoglobinuria (PNH) is a rare condition, many people may struggle to find the support they need. One patient advocate offers ways to cope. Paroxysmal nocturnal ...

(RTTNews) - Swiss drug major Novartis AG (NVS) announced Friday that Fabhalta (iptacopan) has received a positive opinion from the Committee for Medicinal Products for Human Use or CHMP of the ...

Ilene Weitz, MD, discusses research on several new therapies for paroxysmal nocturnal hemoglobinuria (PNH) with promising clinical impact presented at ASH 2024. The APPLY-PNH and APPOINT-PNH studies ...